Intracerebral Hemorrhage

In adult patients with acute spontaneous intracerebral hemorrhage treated within 8 hours of onset, does tranexamic acid, compared with placebo, improve functional outcome (mRS score) at 90 days?

In adult patients (≥18 years) with spontaneous supratentorial intracerebral hemorrhage (volume 10-60 mL, GCS 5-12, pre-ICH mRS 0-1), does early surgical hematoma evacuation (within 24 hours) plus medical care, compared with initial conservative medical care alone, improve functional outcome (mRS score) at 180 days?

In adult patients with acute spontaneous intracerebral hemorrhage and a CT angiography spot sign, treated within 4.5 hours of onset, does tranexamic acid, compared with placebo, reduce hematoma expansion at 24 hours?

In adult patients with spontaneous superficial lobar intracerebral hemorrhage (10-100 mL, GCS ≥6T/7), does a policy of early surgical hematoma evacuation by craniotomy plus best medical treatment, compared with best medical treatment alone (with delayed surgery if needed), improve outcome at 6 months?

In adult patients with spontaneous supratentorial intracerebral hemorrhage, does a policy of early surgical hematoma evacuation plus best medical treatment, compared with best medical treatment alone (with delayed surgery if needed), improve outcome at 6 months?

In adult patients (GCS ≥8) with spontaneous supratentorial intracerebral hemorrhage who were on antiplatelet therapy and presented within 6 hours, does platelet transfusion plus standard care, compared with standard care alone, reduce death or dependence at 3 months?

In adult patients (18-80 years) with spontaneous supratentorial intracerebral hemorrhage (volume ≥30 mL, GCS 4-14), does minimally invasive catheter evacuation followed by alteplase instillation, compared with standard medical care alone, improve functional outcome (mRS 0-3) at 365 days?

In critically ill adult patients with acute vascular brain injury (ischemic stroke, ICH, or SAH), does active fever prevention targeting 37.0°C using an automated surface device, compared with standard reactive fever treatment, improve functional outcome at 3 months?

In patients with acute intracerebral hemorrhage does intensive blood pressure control (target systolic BP <140 mmHg) improving functional outcome at 90 days as compared with standard care (target systolic BP <180 mmHg)?

In adult patients with VKA-associated intracerebral hemorrhage (INR ≥2.0, symptoms <12h), does prothrombin complex concentrate (PCC) compared with fresh frozen plasma (FFP), both with vitamin K, lead to more rapid and effective INR normalization and affect hematoma expansion and clinical outcomes?

In adult patients (18-80 years) with primary spontaneous supratentorial intracerebral hemorrhage, does deferoxamine mesylate (32 mg/kg/day for 3 days) initiated within 24 hours, compared with placebo, show sufficient promise of improving functional outcome (mRS 0-2) at 90 days to warrant a phase 3 trial (i.e., not futile)?

In adult patients with acute intracerebral hemorrhage treated within 4 hours of onset, does recombinant activated factor VII (rFVIIa) at doses of 20 μg/kg or 80 μg/kg, compared with placebo, reduce death or severe disability at 90 days?

In adult patients (18-80 years) with spontaneous supratentorial intracerebral hemorrhage (lobar or basal ganglia, volume 30-80 mL, GCS 5-14), does early minimally invasive parafascicular surgery (MIPS) plus medical management, compared with medical management alone, improve functional outcome (utility-weighted mRS) at 180 days?

In adult patients (18-75 years) with spontaneous supratentorial ICH (<30 mL) and obstructive IVH requiring an EVD, does intraventricular administration of alteplase via the EVD, compared with EVD management with or without saline irrigation, improve functional outcome at 180 days?

In patients with acute intracerebral hemorrhage and SBP ≥180 mmHg, does intensive blood pressure control (target SBP 110-139 mmHg) reduce death or disability at 3 months compared with standard care (target SBP 140-179 mmHg)?

In adult patients with acute major bleeding (including ICH) associated with recent use of a factor Xa inhibitor, does andexanet alfa, compared with usual care, result in better hemostatic efficacy and improved clinical outcomes?